Found 437 clinical trials
A First -in Human Phase I, Non-randomized, Open-label, Multi-center Dose Escalation Trial of BI 764532 Administered by Repeated Intravenous Infusions in Patients With Small Cell Lung Carcinoma and Other Neuroendocrine Neoplasms Expressing DLL3
To determine the maximum tolerated dose(s) (MTD) or the Recommended Dose for Expansion (RDE) and dosing regimen for further development of BI 764532. The MTDs will be defined based on the frequency of patients experiencing dose limiting toxicities (DLTs) during the MTD evaluation period in studied regimens. The RDE will …
- 10 views
- 20 Sep, 2022
- 9 locations
Phase 2 Study of TVB-2640 in KRAS Non-Small Cell Lung Carcinomas
This is a prospective one-arm, two-stage phase 2 trial of TVB-2640 in KRAS mutant NSCLC patients. 13 patients will be treated with a minimum of 1 cycle of TVB-2640 therapy over 8 weeks.
- 1 views
- 06 Mar, 2022
- 1 location
A Clinical Study of TQB3616 Capsules Combined With Anlotinib Hydrochloride Capsules or Standard Chemotherapy Second-line and Above in the Treatment of Advanced Lung Cancer
This is an open, multi-cohort, exploratory phase II study on the safety and efficacy of TQB3616 combined with Anlotinib hydrochloride capsules or standard chemotherapy in the treatment of advanced lung cancer.
- 0 views
- 29 Sep, 2021
- 7 locations
ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma (ABC-lung)
ETOP 15-19 ABC-lung is an international, multi-centre open-label, randomized phase II trial with two non-comparative parallel arms of atezolizumab plus bevacizumab with carboplatin-paclitaxel (Arm A) or atezolizumab, bevacizumab and pemetrexed (Arm B) in patients with stage IIIB-IV non-squamous non-small cell lung cancer (NSCLC) harbouring EGFR mutations after failure of standard …
- 42 views
- 04 Oct, 2022
- 18 locations
RBN-2397 in Combination With Pembrolizumab in Patients With SCCL
RBN-2397 inhibits PARP7, an enzyme that is switched on by cancer stresses, such as the toxins in cigarette smoke. Cancer cells use PARP7 to hide from the immune system by stopping the cell from sending a signal (Type 1 interferon) that tells the immune system that something is wrong and …
- 0 views
- 04 Oct, 2022
- 14 locations
Educating Smokers About Lung Cancer Screening Using Tobacco Quitlines
This implementation study will examine the best ways to refer heavy smokers to information about lung cancer screening.
- 0 views
- 26 Mar, 2022
Mass Screening With Low-Dose CT for Lung Cancer in Guangzhou
A single-arm, prospective study to explore the incidence of lung cancer, the high-risk factor of lung cancer, and the cost-effectiveness of early screening of lung cancer in the general population over 40 years old with low-dose computed tomography in Guangzhou, China
- 0 views
- 09 Apr, 2022
- 1 location
HANSE - Holistic Implementation Study Assessing a Northern German Interdisciplinary Lung Cancer Screening Effort
The HANSE study is primarily intended as a pilot to provide evidence that a holistic and effective lung cancer screening program can be implemented in Germany and that such a screening program can be integrated in the current infrastructure of certified lung cancer centers.
- 1 views
- 17 Jun, 2021
- 3 locations
Digital Outreach Intervention for Lung Cancer Screening (mPATH-Lung)
mPATH-Lung (mobile Patient Technology for Health - Lung) is an innovative digital outreach program that identifies patients who qualify for lung cancer screening and helps them get screened. The study will: 1) Determine the effect of mPATH-Lung on receipt of lung cancer screening in a pragmatic randomized-controlled trial conducted with …
- 0 views
- 04 Oct, 2022
- 2 locations
Navigate - Improving Survival in Vulnerable Lung Cancer Patients
Half of patients with lung cancer face a limited life span of one-year survival, which is characterized by severe physical and psychological symptoms. Differences in stage, comorbidity but also treatment may explain a large proportion of the social inequality in lung cancer survival. Some vulnerable patients may not receive first …
- 0 views
- 04 Oct, 2022
- 4 locations